NEW YORK, July 25, 2017 /PRNewswire/ --
If you want a Stock Review on BPMX, APHB, ATNM, or MTNB then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. On Monday, the NASDAQ Composite ended the day at 6,410.81, up 0.36%; the Dow Jones Industrial Average edged 0.31% lower, to finish at 21,513.17; and the S&P
Menlo Park, California headquartered BioPharmX Corp.'s stock finished Tuesday's session 17.50% lower at $0.38 with a total trading volume of 1.89 million shares, which was higher than their three months average volume of 1.74 million shares. The stock has gained 1.47% since the start of this year. Shares of the Company are trading below their 50-day moving average by 23.82%. Moreover, shares of BioPharmX, which develops and commercializes novel prescription and over-the-counter products that address dermatology and women's health markets, have a Relative Strength Index (RSI) of 26.32. BPMX complete research report is just a click away and free at:
Shares in San Diego, California headquartered AmpliPhi Biosciences Corp. declined 2.33%, ending yesterday's session at $1.05 with a total trading volume of 4.33 million shares, which was higher than their three months average volume of 997.07 thousand shares. The stock has gained 17.91% in the past month. The Company's shares are trading above their 50-day moving average by 20.50%. Moreover, shares of AmpliPhi Biosciences, which focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology, have an RSI of 58.54. The complimentary report on APHB can be downloaded at:
On Tuesday, New York-based Actinium Pharmaceuticals Inc.'s stock saw a decline of 5.39%, to close the day at $0.96. A total volume of 416,330 shares was traded, which was higher than their three months average volume of 390.13 thousand shares. The Company's shares have advanced 10.29% on an YTD basis. The stock is trading below its 50-day moving average by 23.11%. Additionally, shares of Actinium Pharma, which develops targeted payload immunotherapeutics for the treatment of advanced cancers, have an RSI of 30.15. Sign up for your complimentary research report on ATNM at:
Shares in Bedminster, New Jersey-based Matinas BioPharma Holdings Inc. ended the day 0.75% lower at $1.32. A total volume of 204,667 million shares was traded. The stock has gained 85.92% over the last twelve months. The Company's shares are trading below their 50-day moving average by 41.92%. Furthermore, shares of Matinas BioPharma, which focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections, have an RSI of 30.25. Get free access to your research report on MTNB at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Pets can give you diseases. Surprised? You may love your pet but beware! Your pets might be ...
Water is essential to balance body fluids, boost brain function, improve digestion, prevent ...
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...View All